Hyper Personalized Medicine Market 2025 | Customized Drugs, Key Development, Future Growth, Industry Insights

Hyper Personalized Medicine Market reached US$ 256.72 billion in 2024 and is expected to reach US$ 505.26 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Hyper Personalized Medicine Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

By 2040, new cancer cases are projected to reach 29.9 million annually, with 15.3 million deaths. In 2025, cases are expected at 21.3 million, rising to 24.1 million by 2030, according to the International Agency for Research on Cancer.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/hyper-personalized-medicine-market?kb

Recent M&A Highlights

Several notable M&A deals this year reflect strategic investments in hyper-personalized medicine and related precision therapies:

Gilead Sciences acquired Interius BioTherapeutics for $350 million to advance in vivo CAR-T cell therapy, enabling direct generation of CAR T cells inside the body and scalable manufacturing.​

MannKind Corporation is acquiring scPharmaceuticals for $360 million, adding an FDA-approved on-body infuser (FUROSCIX) for heart failure and kidney disease with strong sales growth.​

CorMedix acquired Melinta Therapeutics for $300 million, expanding infectious disease portfolios with hospital-focused marketed products.​

Aurobindo Pharma acquired Lannett for $250 million to enhance US generics and ADHD drug capabilities, aligning with reshoring priorities.

Key Players:

AstraZeneca PLC, GE HealthCare, Illumina, Inc., Novartis AG, Precision Biologics., Abbott Laboratories, ASURAGEN, INC., F. Hoffmann-La Roche Ltd., Achilles Therapeutics plc, QIAGEN N.V. and among others.

FDA and Regulatory Approvals

The FDA approved 50 new molecular entities (NMEs) in 2024, with about 38% classified as personalized medicines, indicating their increasing share of new drug approvals.​

The FDA has approved 25 gene or cell-based therapies to date, underscoring progress in these advanced modalities.​

Personalized medicine accounts for more than a quarter of all new therapeutics approved by the FDA since 2015, with sustained growth in precision and cell therapies.​

Specific approved therapies include CAR-T cell treatments like Kymriah for leukemia and checkpoint inhibitors such as Keytruda.

Growth Forecast Projected:

The Global Hyper Personalized Medicine Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Hyper Personalized Medicine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hyper-personalized-medicine-market?kb

Key Segments:

By Product Type: (Therapeutics, Diagnostics, Software Solutions)

By Technology: (Genomics, Proteomics, Bioinformatics, Artificial Intelligence (AI), Others)

By Application: (Oncology, Cardiology, Neurology, Immunology, Rare Disorders, Infectious Diseases, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hyper-personalized-medicine-market?kb

United States: Key Developments

✅ In September 2025, Tempus expanded its AI-driven genomic profiling services, enabling hyper-personalized cancer treatment plans.

✅ In August 2025, Foundation Medicine launched a new liquid biopsy panel, allowing real-time monitoring of treatment efficacy for precision oncology.

✅ In July 2025, Grail announced partnerships with major U.S. hospitals to implement multi-cancer early detection tests at scale.

✅ In June 2025, 23andMe integrated pharmacogenomics insights into its consumer reports, supporting personalized medication recommendations.

✅ In May 2025, Invitae rolled out AI-enhanced genetic counseling platforms to optimize patient-specific treatment strategies.

Japan: Key Developments

✅ In September 2025, Riken introduced a next-gen single-cell sequencing platform to accelerate personalized medicine research.

✅ In August 2025, Fujifilm Diosynth Biotechnologies started clinical trials for patient-specific gene therapies in oncology.

✅ In July 2025, Takeda Pharmaceuticals launched a precision medicine initiative focusing on rare diseases with tailored treatment regimens.

✅ In June 2025, Canon Medical Systems deployed AI-enabled imaging tools to improve diagnostics and treatment personalization in hospitals.

✅ In May 2025, Sysmex Corporation enhanced its liquid biopsy diagnostics, supporting precision therapy decisions for hematologic cancers.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/hyper-personalized-medicine-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.